Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
NRIX

NRIX - Nurix Therapeutics, Inc. Stock Price, Fair Value and News

10.55USD+0.51 (+5.08%)Market Closed
Watchlist

Market Summary

USD10.55+0.51
Market Closed
5.08%

NRIX Alerts

  • ARK Investment Management LLC reported owning 6.59% of NRIX [2024-01-29]
  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

NRIX Stock Price

View Fullscreen

NRIX RSI Chart

NRIX Valuation

Market Cap

515.8M

Price/Earnings (Trailing)

-3.58

Price/Sales (Trailing)

6.7

EV/EBITDA

-2.47

Price/Free Cashflow

-5.75

NRIX Price/Sales (Trailing)

NRIX Profitability

EBT Margin

-234.27%

Return on Equity

-71.8%

Return on Assets

-40.48%

Free Cashflow Yield

-17.4%

NRIX Fundamentals

NRIX Revenue

Revenue (TTM)

77.0M

Rev. Growth (Yr)

123.49%

Rev. Growth (Qtr)

-17.91%

NRIX Earnings

Earnings (TTM)

-143.9M

Earnings Growth (Yr)

10.19%

Earnings Growth (Qtr)

-13.45%

Breaking Down NRIX Revenue

Last 7 days

11.5%

Last 30 days

5.3%

Last 90 days

56.7%

Trailing 12 Months

-15.3%

How does NRIX drawdown profile look like?

NRIX Financial Health

Current Ratio

3.4

NRIX Investor Care

Shares Dilution (1Y)

3.43%

Diluted EPS (TTM)

-2.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202341.7M60.9M68.6M77.0M
202234.4M38.7M39.2M38.6M
202120.0M22.9M29.0M29.8M
202024.7M19.5M13.0M17.8M
201900031.1M

Tracking the Latest Insider Buys and Sells of Nurix Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 16, 2024
van houte hans
sold
-68,222
10.0151
-6,812
chief financial officer
Jan 30, 2024
hansen gwenn
sold
-18,649
7.9902
-2,334
chief scientific officer
Jan 30, 2024
hansen gwenn
acquired
-
-
5,207
chief scientific officer
Jan 30, 2024
van houte hans
sold
-13,351
7.9902
-1,671
chief financial officer
Jan 30, 2024
ring christine
acquired
-
-
3,924
chief legal officer
Jan 30, 2024
van houte hans
acquired
-
-
4,886
chief financial officer
Jan 30, 2024
ring christine
sold
-14,062
7.9902
-1,760
chief legal officer
Dec 20, 2023
van houte hans
sold
-35,421
10.0031
-3,541
chief financial officer
Dec 19, 2023
van houte hans
sold
-109,093
10.003
-10,906
chief financial officer
Oct 31, 2023
ring christine
sold
-6,403
5.1974
-1,232
chief legal officer

1–10 of 50

Which funds bought or sold NRIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
35.64
221,866
505,866
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-87.67
-1,287,000
249,000
0.02%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
0.5
5,973,000
24,665,000
-%
Feb 15, 2024
Virtus ETF Advisers LLC
added
14.93
36,048
106,874
0.07%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
93.00
93.00
-%
Feb 15, 2024
BARCLAYS PLC
added
1.89
179,000
709,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
524
678,223
772,370
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-78.44
-180,189
71,167
-%
Feb 14, 2024
MARSHALL WACE, LLP
sold off
-100
-1,002,220
-
-%
Feb 14, 2024
Engineers Gate Manager LP
new
-
211,704
211,704
0.01%

1–10 of 48

Are Funds Buying or Selling NRIX?

Are funds buying NRIX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NRIX
No. of Funds

Unveiling Nurix Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
6.18%
2,997,830
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
4.9%
2,391,866
SC 13G/A
Feb 14, 2024
redmile group, llc
9.9%
5,021,886
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
9.99%
4,952,452
SC 13G/A
Feb 14, 2024
sands arthur t
5.4%
2,707,896
SC 13G
Feb 13, 2024
vanguard group inc
5.36%
2,598,097
SC 13G
Feb 09, 2024
wasatch advisors lp
-
0
SC 13G/A
Feb 09, 2024
morgan stanley
6.4%
3,099,198
SC 13G
Jan 29, 2024
ark investment management llc
6.59%
3,194,999
SC 13G
Jan 24, 2024
blackrock inc.
9.6%
4,643,736
SC 13G/A

Recent SEC filings of Nurix Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Feb 16, 2024
144
Notice of Insider Sale Intent
Feb 16, 2024
4
Insider Trading
Feb 15, 2024
10-K
Annual Report
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
8-K
Current Report
Feb 15, 2024
S-8
Employee Benefits Plan
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Nurix Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Nurix Therapeutics, Inc. News

Latest updates
Zacks Investment Research100 minutes ago

Nurix Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-17.9%15,159,00018,467,00030,676,00012,685,0006,783,00010,791,00011,432,0009,621,0007,396,00010,252,0007,091,0005,011,0006,689,0004,085,0004,182,0002,864,0001,862,00010,580,0009,439,0009,234,000
Operating Expenses3.4%60,493,00058,479,00057,441,00055,637,00055,473,00057,509,00057,147,00052,365,00045,349,00039,249,00033,505,00029,533,00026,697,00023,277,00017,412,00015,417,000-13,192,000--
  S&GA Expenses1.5%10,780,00010,623,00011,678,0009,821,0009,367,0009,748,0009,654,0009,228,0008,818,0008,343,0007,511,0006,530,0006,251,5004,338,0003,270,0002,450,000-2,184,000--
  R&D Expenses3.9%49,713,00047,856,00045,763,00045,816,00046,106,00047,761,00047,493,00043,137,00036,531,00030,906,00025,994,00023,003,00020,445,50018,939,00014,142,00012,967,000-11,008,000--
EBITDA Margin11.1%-2.24-2.52-2.85-4.18-4.53-4.25-3.90-3.85-3.84-3.33-3.78-3.67--------
Income Taxes---------52,000-100,000100,00071,00053,000--20,587,00011,000-10,000--
Earnings Before Taxes------46,717,000-45,709,000-45,401,000-42,533,000-37,658,000-28,958,000-26,243,000-24,204,000-19,873,000-18,517,000-13,007,000-12,380,000--2,417,000--
EBT Margin10.9%-2.34-2.63-2.96-4.33-4.67-4.37-3.99-3.94-3.93-3.42-3.88-3.79--------
Net Income-13.4%-41,956,000-36,982,000-24,277,000-40,733,000-46,717,000-45,709,000-45,401,000-42,533,000-37,702,000-28,835,000-26,382,000-24,275,000-19,914,000-18,517,0007,580,000-12,391,000-13,519,000-2,427,000-3,068,000-2,685,000
Net Income Margin13.7%-1.87-2.17-2.58-4.28-4.67-4.37-3.99-3.94-3.94-3.42-3.89-2.76--------
Free Cashflow155.3%24,104,000-43,592,000-19,549,000-50,729,000-40,520,000-49,726,000-35,703,000-46,102,000-31,773,000-31,837,000-33,626,0007,210,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets15.4%35630835137041745939443847749351839739641228916744.00
  Current Assets10.3%296268290288318355307280311358396311298364--39.00
    Cash Equivalents29.1%55.0042.0059.0034.0064.0048.0042.0079.0081.0014718812611926615956.0035.00
  Net PPE1.4%17.0017.0018.0018.0017.0017.0016.0014.0011.0010.008.007.007.007.00--4.00
Liabilities108.5%15574.0091.0096.0011311712813213411812012710610487.0070.0054.00
  Current Liabilities41.4%87.0061.0072.0065.0071.0068.0073.0066.0066.0051.0047.0048.0045.0041.00--16.00
Shareholder's Equity-14.3%2002342602743043432673063423753982702903084.003.003.00
  Retained Earnings-8.3%-545-503-466-442-401-354-308-263-220-183-154-127-103-83.78---60.46
  Additional Paid-In Capital1.1%746738728719709701579571564558552398394391--3.00
Shares Outstanding0.4%49.0049.0048.0047.0047.0051.0045.0045.0045.0042.0041.0039.00-----
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations164.9%27.00-41.13-18.47-48.45-37.95-46.31-32.91-42.63-30.91-29.97-31.538.00-20.48-6.14-14.4341.00--
  Share Based Compensation-5.0%8.008.009.008.008.007.007.006.005.004.004.003.003.001.000.000.00--
Cashflow From Investing-163.1%-14.3723.0044.0016.0055.00-63.08-4.7640.00-36.52-12.23-57.11-2.39-124-108-2.34-19.42--
Cashflow From Financing-99.6%0.002.000.001.00-0.131150.001.001.002.001501.00-1.132201200.00--

NRIX Income Statement

2023-11-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Nov. 30, 2023
Nov. 30, 2022
Total revenue$ 76,987$ 38,627
Operating expenses:  
Research and development189,148184,497
General and administrative42,90237,997
Total operating expenses232,050222,494
Loss from operations(155,063)(183,867)
Interest and other income, net11,1153,507
Net loss$ (143,948)$ (180,360)
Net loss per share, basic (in USD per share)$ (2.65)$ (3.71)
Net loss per share, diluted (in USD per share)$ (2.65)$ (3.71)
Weighted-average number of shares outstanding, diluted (in shares)54,337,90148,607,990
Weighted-average number of shares outstanding, basic (in shares)54,337,90148,607,990
Collaboration revenue  
Total revenue$ 56,987$ 38,627
License revenue  
Total revenue$ 20,000$ 0

NRIX Balance Sheet

2023-11-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Nov. 30, 2023
Nov. 30, 2022
Current assets:  
Cash and cash equivalents$ 54,627$ 64,474
Marketable securities, current233,281244,667
Prepaid expenses and other current assets7,5959,308
Total current assets295,503318,449
Marketable securities, non-current7,42163,879
Operating lease right-of-use assets31,14212,345
Property and equipment, net16,80817,163
Restricted cash901901
Other assets3,8234,022
Total assets355,598416,759
Current liabilities:  
Accounts payable6,4015,064
Accrued expenses and other current liabilities24,97022,428
Operating lease liabilities, current7,4895,530
Deferred revenue, current48,09837,633
Total current liabilities86,95870,655
Operating lease liabilities, net of current portion23,1256,434
Deferred revenue, net of current portion45,02235,974
Total liabilities155,105113,063
Commitments and contingencies (Note 6)
Stockholders’ equity:  
Preferred stock, $0.001 par value— 10,000,000 shares authorized as of November 30, 2023 and 2022; no shares issued and outstanding as of November 30, 2023 and 202200
Common stock, $0.001 par value— 500,000,000 shares authorized as of November 30, 2023 and 2022; 48,718,552 and 47,172,299 shares issued and outstanding as of November 30, 2023 and 2022, respectively4947
Additional paid-in capital746,299709,220
Accumulated other comprehensive loss(655)(4,319)
Accumulated deficit(545,200)(401,252)
Total stockholders’ equity200,493303,696
Total liabilities and stockholders’ equity$ 355,598$ 416,759
NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
 CEO
 WEBSITEwww.nurixtx.com
 EMPLOYEES297

Nurix Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Nurix Therapeutics, Inc.? What does NRIX stand for in stocks?

NRIX is the stock ticker symbol of Nurix Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nurix Therapeutics, Inc. (NRIX)?

As of Thu Feb 22 2024, market cap of Nurix Therapeutics, Inc. is 515.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NRIX stock?

You can check NRIX's fair value in chart for subscribers.

What is the fair value of NRIX stock?

You can check NRIX's fair value in chart for subscribers. The fair value of Nurix Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nurix Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NRIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nurix Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether NRIX is over valued or under valued. Whether Nurix Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Nurix Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NRIX.

What is Nurix Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, NRIX's PE ratio (Price to Earnings) is -3.58 and Price to Sales (PS) ratio is 6.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NRIX PE ratio will change depending on the future growth rate expectations of investors.